

LAHIVE
&
COCKFIELD
LLP

COUNSELLORS AT LAW
28 STATE STREET
BOSTON, MASSACHUSETTS 02109-1784
TELEPHONE (617) 227-7400
FAX (617) 742-4214
www.lahive.com

JOHN A. LAHIVE, JR. (1929-1997)
THOMAS V. SMURZYNSKI
GIULIO A. DeCONTI, JR.
ELIZABETH A. HANLEY
AMY BAKER MANDRAGOURAS
ANTHONY A. LAURENTANO
KEVIN J. CANNING
JANE E. REMILLARD
DeANN FORAN SMITH
DEBRA J. MILASINCIC, Ph.D.
WILLIAM A. SCOFIELD, JR.
SIBLEY P. REPPERT
DAVID R. BURNS
JOHN S. CURRAN
SEAN D. DETWEILER
MEGAN E. WILLIAMS, Ph.D.
LISA DiROCCO TYNER
HATHAWAY P. RUSSELL *
MARIA LACCOTRIPE ZACHARAKIS, Ph.D.

MERIDETH C. ARNOLD
DANIELLE L. HERRITT
EUIHOON LEE **
MANEESH GULATI
CYNTHIA M. SOROOS
PETER W. DINI, Ph.D.
MICHAEL J. BASTIAN, Ph.D.
CHRISTOPHER J. McKENNA
VINCENT P. LOCCISANO
JAMES M. McKENZIE

SENIOR COUNSEL
JAMES E. COCKFIELD

OF COUNSEL
JEREMIAH LYNCH
JEANNE M. DIGIORGIO
CYNTHIA L. KANIK, Ph.D.
JOHN D. LANZA

PATENT AGENTS
JONATHAN M. SPARKS, Ph.D.
ANDRINA WILLIAMS ZINK
CRISTIN E. HOWLEY, Ph.D.
JILL ANN MELLO, Ph.D.
CHRISTOPHER E. DRABIK
JAMES H. VELEMA

TECHNICAL SPECIALISTS
CATHERINE M. BISHOP
JACOB G. WEINTRAUB
DEBORAH L. NAGLE, Ph.D.
ANNE JACQUELINE WIZEMAN, Ph.D.
BRIAN C. TRINQUE, Ph.D.
CHRISTOPHER R. COWLES, Ph.D.
W. ELANA WANG
CYNTHIA M. GILBERT
MEAGHAN L. RICHMOND, Ph.D.

* Admitted in TX only
** Admitted in CT only

January 13, 2005

MS Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, Virginia 22313-1450

Re: U.S. Patent Application No.: 10/684206
For: *MOLECULES PREFERENTIALLY ASSOCIATED WITH EFFECTOR T CELLS OR
REGULATORY T CELLS AND METHODS OF THEIR USE*
Inventors: Rao, Patricia *et al.*
Filed: October 9, 2003
Our Ref. No.: TLN-021CP

Dear Sir:


I enclose herewith for filing in the above-identified application the following:

1. Information Disclosure Statement;
2. PTO Form SB-08;
3. Copies of references cited in PTO Form SB-08 (12); and
4. A Return Postcard.


No additional costs are believed to be due in connection with the filing of this Information Disclosure Statement. However, please charge any necessary fees in connection with the enclosed statement to our Deposit Order Account No. 12-0080. For this purpose, a duplicate of this sheet is attached.


I hereby certify that this correspondence is deposited with the United States Postal Service as first class mail in an envelope addressed to: MS Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, Virginia 22313-1450:

January 13, 2005
Date


Megan E. Williams, Esq., Reg. No. 43,270

Respectfully submitted,
LAHIVE & COCKFIELD, LLP


Megan E. Williams, Esq.
Registration No. 43,270
Attorney for Applicants



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re the application of: Rao, Patricia *et al.*

Serial No.: 10/684,206

Filed: October 9, 2003

For: *MOLECULES PREFERENTIALLY
ASSOCIATED WITH EFFECTOR T CELLS OR
REGULATORY T CELLS AND METHODS OF
THEIR USE*

Attorney Docket No.: TLN-021CP

Group Art Unit: 1614

Examiner: Not Yet Assigned

MS Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, Virginia 22313-1450

Certificate of First Class Mailing (37 CFR §1.8(a))

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: MS Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, Virginia 22313-1450 on the date set forth below.

January 13, 2005

Date of Signature and of Mail Deposit

By:

Megan E. Williams, Esq.

Registration No. 43,270

Attorney for Applicants

INFORMATION DISCLOSURE STATEMENT

Dear Sir:

Applicants and their Attorney are aware of the following publications and information, listed on the attached PTO Form SB/08, and in accordance with 37 CFR §1.97 hereby submit these publications for the Examiner's consideration. A copy of the report and each cited publication is enclosed.

This statement is not to be interpreted as a representation that the cited publications are material, that an exhaustive search has been conducted, or that no other relevant information exists. Nor shall the citation of any publication herein be construed *per se* as a representation that such publication is prior art. Moreover,

Applicants understand that the Examiner will make an independent evaluation of the cited publications.

Under 37 CFR § 1.97(b)(3), no additional costs are believed to be due in connection with the filing of this disclosure. If, however, a first Office Action on the merits issues in this application bearing a mailing date prior to the date of this Information Disclosure Statement, please charge the appropriate fee as required under 37 CFR §1.17(p) to our Deposit Order Account No. 12-0080.

Respectfully submitted,
LAHIVE & COCKFIELD, LLP



Megan E. Williams, Esq.
Registration No. 43,270
Attorney for Applicants

28 State Street
Boston, MA 02109
(617) 227-7400

Date: January 13, 2005

AEM/MEW/DLN/rl

Enclosures



PTO/SB/08a/b (08-03)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/B/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Sheet 1 of 1

Complete if Known

Application Number	10/684206
Filing Date	October 9, 2003
First Named Inventor	Rao, Patricia
Art Unit	1614
Examiner Name	Not Yet Assigned
Attorney Docket Number	TLN-021CP

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code ² (if known)			

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)				

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3).⁵
Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible.⁶

NON PATENT LITERATURE DOCUMENTS

Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	A1	Arthur <i>et al.</i> "T cells that help B cell responses to soluble antigen are distinguishable from those producing interleukin 2 on mitogenic or allogeneic stimulation." <i>J. Exp. Med.</i> 1986 Apr 1; 163(4): 774-86	
	A2	Cogé <i>et al.</i> "Structure and expression of the human histamine H ₄ -receptor gene." <i>Biochem Biophys Res Commun.</i> 2001 Jun 8; 284(2): 301-9	
	A3	Finkelman <i>et al.</i> "IL-4 is required to generate and sustain in vivo IgE responses." <i>J. Immunol.</i> 1988 Oct 1; 141(7): 2335-41	
	A4	Lechmann <i>et al.</i> "CD83 on dendritic cells: more than just a marker for maturation." <i>Trends Immunol.</i> 2002 Jun; 23(6): 273-5	
	A5	Mosmann <i>et al.</i> "TH1 and TH2 cells: different patterns of lymphokine secretion lead to different functional properties." <i>Ann. Rev. Immunol.</i> 1989; 7: 145-73	
	A6	Nikolova <i>et al.</i> "BY55/CD160 acts as a co-receptor in TCR signal transduction of a human circulating cytotoxic effector T lymphocyte subset lacking CD28 expression." <i>Int. Immunol.</i> 2002 May; 14(5): 445-51	
	A7	Paliard <i>et al.</i> "Simultaneous production of IL-2, IL-4, and IFN- γ by activated human CD4 ⁺ and CD8 ⁺ T cell clones." <i>J. Immunol.</i> 1988 Aug 1; 141(3): 849-55	
	A8	Paul <i>et al.</i> "Lymphocyte responses and cytokines." <i>Cell.</i> 1994 Jan 28; 76(2): 241-51	
	A9	Tangye <i>et al.</i> "Functional requirements for interactions between CD84 and Src homology 2 domain-containing proteins and their contribution to human T cell activation." <i>J. Immunol.</i> 2003 Sep 1; 171(5): 2485-95	
	A10	Vamum-Finney <i>et al.</i> "The Notch ligand, Jagged-1, influences the development of primitive hematopoietic precursor cells." <i>Blood.</i> 1998 Jun 1; 91(11): 4084-91	
	A11	Waldmann <i>et al.</i> "Regulating the immune response to transplants: a role for CD4 ⁺ regulatory cells?" <i>Immunity.</i> 2001 Apr; 14(4): 399-406	
	A12	Yvon <i>et al.</i> "Overexpression of the Notch ligand, Jagged-1, induces alloantigen-specific human regulatory T cells." <i>Blood.</i> 2003 Nov 15; 102(10): 3815-21	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.

Examiner Signature	Date Considered
--------------------	-----------------